EE200100075A - 2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid - Google Patents

2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid

Info

Publication number
EE200100075A
EE200100075A EEP200100075A EEP200100075A EE200100075A EE 200100075 A EE200100075 A EE 200100075A EE P200100075 A EEP200100075 A EE P200100075A EE P200100075 A EEP200100075 A EE P200100075A EE 200100075 A EE200100075 A EE 200100075A
Authority
EE
Estonia
Prior art keywords
piperidylbenzimidazole
orl
substituted
compounds
receptor agonists
Prior art date
Application number
EEP200100075A
Other languages
English (en)
Estonian (et)
Inventor
Ito Fumitaka
Noguchi Hirohide
Kondo Hiroshi
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200100075A publication Critical patent/EE200100075A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200100075A 1998-08-06 1999-07-05 2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid EE200100075A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB98/01206 1998-08-06
PCT/IB1999/001239 WO2000008013A2 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists

Publications (1)

Publication Number Publication Date
EE200100075A true EE200100075A (et) 2002-06-17

Family

ID=11004738

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100075A EE200100075A (et) 1998-08-06 1999-07-05 2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid

Country Status (44)

Country Link
US (1) US6172067B1 (sl)
EP (1) EP1102762B1 (sl)
JP (1) JP3367945B2 (sl)
CN (1) CN1317968A (sl)
AP (1) AP2001002063A0 (sl)
AR (1) AR018686A1 (sl)
AT (1) ATE227716T1 (sl)
AU (1) AU749166B2 (sl)
BG (1) BG105301A (sl)
BR (1) BR9912778A (sl)
CA (1) CA2339621C (sl)
CZ (1) CZ2001397A3 (sl)
DE (1) DE69903953T2 (sl)
DK (1) DK1102762T3 (sl)
EA (1) EA200100104A1 (sl)
EE (1) EE200100075A (sl)
ES (1) ES2185357T3 (sl)
GE (1) GEP20033000B (sl)
GT (1) GT199900125A (sl)
HK (1) HK1040188A1 (sl)
HN (1) HN1999000105A (sl)
HR (1) HRP20010089B1 (sl)
HU (1) HUP0103567A3 (sl)
ID (1) ID27212A (sl)
IL (1) IL141029A0 (sl)
IS (1) IS5812A (sl)
MA (1) MA26659A1 (sl)
NO (1) NO20010603L (sl)
NZ (1) NZ509299A (sl)
OA (1) OA11590A (sl)
PA (1) PA8477701A1 (sl)
PE (1) PE20000868A1 (sl)
PL (1) PL346211A1 (sl)
PT (1) PT1102762E (sl)
SI (1) SI1102762T1 (sl)
SK (1) SK1602001A3 (sl)
SV (1) SV1999000099A (sl)
TN (1) TNSN99142A1 (sl)
TR (1) TR200100403T2 (sl)
TW (1) TW513424B (sl)
UY (1) UY25659A1 (sl)
WO (1) WO2000008013A2 (sl)
YU (1) YU8201A (sl)
ZA (1) ZA200100900B (sl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340681B1 (en) * 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
ES2249237T3 (es) 2000-01-05 2006-04-01 Pfizer Inc. Compuestos de bencimidazol como antagonistas del receptor orl1.
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
JP4155029B2 (ja) 2000-11-15 2008-09-24 萬有製薬株式会社 ベンズイミダゾール誘導体
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SI1598339T1 (sl) 2001-04-18 2009-12-31 Euro Celtique Sa Derivati 1-(4-amino.cikloheksil)-1,3-dihidro-2h-benzimidazol-2-ona in sorodne spojine kot nociceptinski analogi in ORL1 ligandi za zdravljenje bolečine
CN1516584A (zh) 2001-04-18 2004-07-28 ŷ�����ǹɷ����޹�˾ 螺吡唑化合物
CA2443938C (en) 2001-04-18 2010-06-22 R. Richard Goehring Spiroindene and spiroindane compounds as opioid ligands useful for treating pain
CA2444489C (en) * 2001-04-18 2010-06-22 Euro-Celtique, S.A. Benzimidazolone compounds
KR100855204B1 (ko) * 2001-04-18 2008-09-01 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
CA2490386A1 (en) * 2001-07-02 2003-01-16 Omeros Corporation Method for producing analgesia comprising administration of an opioid receptor agonist in rotation with an opioid receptor like-1 receptor agonist
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
US7812035B2 (en) * 2001-12-11 2010-10-12 Sepracor Inc. 4-substituted piperidines, and methods of use thereof
DK1491212T3 (da) 2002-03-29 2012-10-29 Mitsubishi Tanabe Pharma Corp Middel til behandling af søvnforstyrrelser
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
GB0315203D0 (en) * 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
AR045939A1 (es) 2003-09-25 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
WO2006038738A1 (ja) * 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited 受容体機能調節剤
EP1838306B1 (en) 2005-01-11 2010-11-17 NeuroSearch A/S Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
AU2007271243A1 (en) * 2006-07-03 2008-01-10 Neurosearch A/S Combinations of monoamine reuptake inhibitors and potassium channel activators
SI2076506T1 (sl) * 2007-01-16 2011-01-31 Purdue Pharma Lp Heterociklično substituirani piperidini kot ORL-1 ligandi
EP3101018B1 (en) * 2007-08-31 2019-03-06 Purdue Pharma L.P. Substituted-quinoxaline-type-piperidine compounds and the uses thereof
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
EP2324013B3 (en) 2008-07-21 2014-10-22 Purdue Pharma LP Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
SG10201505997TA (en) 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
WO2013103598A2 (en) 2012-01-06 2013-07-11 Novus International Inc. Sulfoxide-based surfactants
WO2013119959A1 (en) 2012-02-09 2013-08-15 Novus International Inc. Heteroatom containing cyclic dimers
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
CA2878617A1 (en) 2012-07-12 2014-01-16 Houston Stephen Smith Matrix and layer compositions for protection of bioactives
US9085561B2 (en) * 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014153529A1 (en) 2013-03-22 2014-09-25 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
DK3119762T3 (da) * 2014-03-20 2021-08-30 Capella Therapeutics Inc Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
SG11201803979PA (en) 2015-11-12 2018-06-28 Novus Int Inc Sulfur-containing compounds as solvents
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
JPS5297978A (en) * 1976-06-02 1977-08-17 Yoshitomi Pharmaceut Ind Ltd Preparation of alicyclic derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
DE69626522T2 (de) 1995-08-15 2003-12-24 Euroscreen S.A., Bruessel/Bruxelles Peptide mit pronociceptiveigenschaften
US5866346A (en) 1995-09-27 1999-02-02 Indiana Unversity Foundation Methods of using dynorphins as ligands for XOR1 receptor
WO1997040035A1 (en) * 1996-04-19 1997-10-30 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
EP0813065A3 (en) 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Modulation of LC132 (opioid-like) receptor function
EP0829481A1 (en) * 1996-09-16 1998-03-18 Pfizer Inc. Morphinan hydroxamic acid compounds
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
WO1998054168A1 (fr) 1997-05-30 1998-12-03 Banyu Pharmaceutical Co., Ltd. Derives de 2-0xoimidazole
WO1999003880A1 (en) 1997-07-15 1999-01-28 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1

Also Published As

Publication number Publication date
AR018686A1 (es) 2001-11-28
EP1102762B1 (en) 2002-11-13
PA8477701A1 (es) 2000-09-29
WO2000008013A3 (en) 2000-03-23
TW513424B (en) 2002-12-11
YU8201A (sh) 2003-07-07
TNSN99142A1 (fr) 2005-11-10
GT199900125A (es) 2001-01-27
NO20010603D0 (no) 2001-02-05
SK1602001A3 (en) 2002-09-10
HRP20010089A2 (en) 2002-02-28
PL346211A1 (en) 2002-01-28
AU749166B2 (en) 2002-06-20
WO2000008013A2 (en) 2000-02-17
CA2339621A1 (en) 2000-02-17
SI1102762T1 (sl) 2003-04-30
EA200100104A1 (ru) 2001-08-27
CN1317968A (zh) 2001-10-17
JP3367945B2 (ja) 2003-01-20
DE69903953T2 (de) 2003-03-27
HUP0103567A2 (hu) 2002-02-28
GEP20033000B (en) 2003-06-25
JP2002522431A (ja) 2002-07-23
PT1102762E (pt) 2003-02-28
AU4385999A (en) 2000-02-28
HRP20010089B1 (en) 2003-04-30
BG105301A (en) 2001-12-29
UY25659A1 (es) 2000-02-23
IS5812A (is) 2001-01-16
AP2001002063A0 (en) 2001-03-31
SV1999000099A (es) 2000-09-05
ES2185357T3 (es) 2003-04-16
HK1040188A1 (zh) 2002-05-31
NZ509299A (en) 2003-05-30
ID27212A (id) 2001-03-08
EP1102762A2 (en) 2001-05-30
DK1102762T3 (da) 2002-12-16
CA2339621C (en) 2005-04-05
ATE227716T1 (de) 2002-11-15
BR9912778A (pt) 2001-09-25
DE69903953D1 (de) 2002-12-19
US6172067B1 (en) 2001-01-09
ZA200100900B (en) 2002-08-28
MA26659A1 (fr) 2004-12-20
HUP0103567A3 (en) 2003-01-28
PE20000868A1 (es) 2000-08-31
HN1999000105A (es) 2000-11-11
TR200100403T2 (tr) 2001-07-23
CZ2001397A3 (cs) 2002-05-15
NO20010603L (no) 2001-04-05
OA11590A (en) 2004-08-18
IL141029A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
EE200100075A (et) 2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid
NO20010467L (no) Ligander med høy affinitet for nociceptinreseptor ORL-1
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
ATE256141T1 (de) N-pyrazol a2a rezeptor agonisten
DK1161232T3 (da) Hydroxydiphenylureasulfonamider som IL-8-receptorantagonister
DE69926861D1 (de) Beta 2- adrenergische rezeptoragonisten
IS5706A (is) Adenosín A3 viðtakastillar
DK2332915T3 (da) beta2-Adrenoceptoragonister
EE200200588A (et) Bensoamiidpiperidiinühendid kui substants P antagonistid
ATE280157T1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
ATE240342T1 (de) Propargylphenyl-äther a2a rezeptoragonisten
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
ATE272632T1 (de) Muskarin-rezeptor antagonisten
ID26223A (id) Antagonis reseptor vitronektin
ID28811A (id) Antagonis reseptor vitronektin
EE200000733A (et) Tetrahüdrokinoliini derivaadid kui glütsiini antagonistid
IS5897A (is) Úreídópíperidín afleiður sem valvís NK3 viðtakamótlyf fyrir manneskjur
NO20010353D0 (no) IL-8 reseptor-antagonist
ID25461A (id) Turunan 2-ariletil-(piperidin-4-ilmetil)amina sebagai antagonis reseptor muskarinik